Impax Drug Patent Portfolio
Impax owns 4 orange book drugs protected by 44 US patents Given below is the list of Impax's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11986449 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12109185 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12194150 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12201596 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12263148 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12263149 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12295931 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12303481 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12303482 | Levodopa dosing regimen | 21 Dec, 2041 | Active |
| US12370163 | Levodopa Dosing Regimen | 21 Dec, 2041 | Active |
| US12447139 | Levodopa Dosing Regimen | 21 Dec, 2041 | Active |
| US12453710 | Levodopa Dosing Regimen | 21 Dec, 2041 | Active |
| US12458616 | Levodopa Dosing Regimen | 21 Dec, 2041 | Active |
| US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12128141 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12178918 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12178919 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12274793 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12303605 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | 07 Oct, 2034 | Active |
| US12403099 | Muco-Adhesive, Controlled Release Formulation Of Levodopa And/Or Esters Of Levodopa And Uses Thereof | 07 Oct, 2034 | Active |
| US12491164 | Muco-Adhesive, Controlled Release Formulation Of Levodopa And/Or Esters Of Levodopa And Uses Thereof | 07 Oct, 2034 | Active |
| US8377474 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US8454998 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US8557283 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9089607 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9089608 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9463246 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9533046 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US9901640 | Controlled release formulations of levodopa and uses thereof | 26 Dec, 2028 | Active |
| US7905352 | Kits containing medicine injection devices and containers | 12 Apr, 2027 | Active |
| US7621891 | Method and apparatus for delivering epinephrine | 04 Feb, 2025 | Expired |
| US10166334 | Medicine injection apparatuses | 21 Jan, 2025 | Expired |
| US10166344 | Injection needle assembly | 21 Jan, 2025 | Expired |
| US7297136 | Medicine injection devices and methods | 18 Jan, 2025 | Expired |
| US7094427 | Combination immediate release controlled release levodopa/carbidopa dosage forms | 29 May, 2022 | Expired |
| US5665071 | Reloadable automatic or manual emergency injection system | 27 May, 2013 | Expired |
Latest Legal Activities on Impax's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Impax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Dispatch to FDC | 24 Sep, 2025 | US12447139 |
| Application Is Considered Ready for Issue | 24 Sep, 2025 | US12447139 |
| Application Is Considered Ready for Issue | 23 Sep, 2025 | US12453710 |
| Dispatch to FDC | 23 Sep, 2025 | US12453710 |
| Issue Fee Payment Verified | 22 Sep, 2025 | US12453710 |
| Amendment after Notice of Allowance (Rule 312) | 22 Sep, 2025 | US12491164 |
| Issue Fee Payment Verified | 22 Sep, 2025 | US12447139 |
| Issue Fee Payment Received | 22 Sep, 2025 | US12447139 |
| Issue Fee Payment Received | 22 Sep, 2025 | US12453710 |
| Email Notification | 17 Sep, 2025 | US12491164 |
| Mail Notice of Allowance | 17 Sep, 2025 | US12491164 |
| Notice of Allowance Data Verification Completed | 16 Sep, 2025 | US12491164 |
| Recordation of Patent Grant Mailed | 09 Sep, 2025 | US12403099 |
| Patent Issue Date Used in PTA Calculation | 02 Sep, 2025 | US12403099 |
| Patent eGrant Notification | 02 Sep, 2025 | US12403099 |
Impax Drug Patents' Oppositions Filed in EPO
Impax drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 07, 2021, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP08866933A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08866933A | Jan, 2021 | Luigi, Rumi | Granted and Under Opposition |
| EP08866933A | Jan, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
Impax's Family Patents
Impax drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 37.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Recent FDA approvals and tentative approvals for Impax
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Duloxetine Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 18 Nov, 2010 |
| Venlafaxine Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 16 Oct, 2007 |
| Oxycodone Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 04 Sep, 2003 |
Impax Drug List
Given below is the complete list of Impax's drugs and the patents protecting them.
1. Adrenaclick
Adrenaclick is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7905352 | Kits containing medicine injection devices and containers |
12 Apr, 2027
(1 year, 13 days from now)
| Active |
| US10166334 | Medicine injection apparatuses |
21 Jan, 2025
(1 year, 2 months ago)
| Expired |
| US10166344 | Injection needle assembly |
21 Jan, 2025
(1 year, 2 months ago)
| Expired |
| US5665071 | Reloadable automatic or manual emergency injection system |
27 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adrenaclick's drug page
2. Crexont
Crexont is protected by 29 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11986449 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12109185 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12194150 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12201596 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12263148 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12263149 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12295931 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12303481 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12303482 | Levodopa dosing regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12370163 | Levodopa Dosing Regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12447139 | Levodopa Dosing Regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12453710 | Levodopa Dosing Regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US12458616 | Levodopa Dosing Regimen |
21 Dec, 2041
(15 years from now)
| Active |
| US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12128141 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12178918 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12178919 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12274793 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12303605 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12403099 | Muco-Adhesive, Controlled Release Formulation Of Levodopa And/Or Esters Of Levodopa And Uses Thereof |
07 Oct, 2034
(8 years from now)
| Active |
| US12491164 | Muco-Adhesive, Controlled Release Formulation Of Levodopa And/Or Esters Of Levodopa And Uses Thereof |
07 Oct, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crexont's drug page
3. Rytary
Rytary is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8377474 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US8454998 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US8557283 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US9089607 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US9089608 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US9463246 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US9533046 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US9901640 | Controlled release formulations of levodopa and uses thereof |
26 Dec, 2028
(2 years from now)
| Active |
| US7094427 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
29 May, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rytary's drug page
4. Twinject
Twinject is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7621891 | Method and apparatus for delivering epinephrine |
04 Feb, 2025
(1 year, 1 month ago)
| Expired |
| US7297136 | Medicine injection devices and methods |
18 Jan, 2025
(1 year, 2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twinject's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List